ClinicalTrials.gg
Not yet recruitingNCT07368985Updated Jan 27, 2026

Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer

A Phase 2 interventional study of pembrolizumab and lenvatinib in Cervical Cancer by FIGO Stage 2018, Squamous Cell Carcinoma FIGO 2018 Stage IIIA, IIIB, IIIC1-IIIC2 and Adenocarcinoma or Adeno-squamous Carcinoma Stage IB3-IIIC2, sponsored by Prof. Dr. Remi A. Nout. Not yet recruiting at 1 site in Netherlands. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-27.

Sponsored by Prof. Dr. Remi A. Nout · Phase 2, Interventional, and Treatment

How we know · 5 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
87
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 13 studies testing pembrolizumab in Adenocarcinoma — 3 open to participants now, 5 under way, none of them phase 3. pembrolizumab · Adenocarcinoma.

Planned enrollment
2nd of 13
87 · median 26
Started
2026
the only one that year
Phase 2
12 of 13
3 open now
Registered
13th of 13
by date
Lead sponsor
1 of 13
Prof. Dr. Remi A. Nout

Among the 13 studies testing pembrolizumab in Adenocarcinoma, this one is the 2nd largest by planned enrollment, is the only one that started in 2026, is one of 12 in phase 2, and was the 13th registered.

Adenocarcinoma

622 studies on the registry are indexed under Adenocarcinoma; 149 are open to participants now.

Browse Adenocarcinoma studies →

Open to participants now

3 of the 13 studies testing pembrolizumab in Adenocarcinoma are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 113 Adenocarcinoma studies recruiting now, 84 (74%) set no upper age limit and 11 (10%) stop at 75 or younger; 7 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing pembrolizumab in Adenocarcinoma, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if the combination of Pembrolizumab and Lenvatinib works to treat locally advanced cervical cancer in adults that will undergo primary chemoradiation and brachytherapy. It will also learn about the safety of the combination of Pembrolizumab and Lenvatinib. The main questions it aims to answer are:

  • Does the combination of Pembrolizumab and Lenvatinib improve progression free survival at two years after treatment?
  • What side effects do participants have when taking the combination of Pembrolizumab and Lenvatinib? Researchers will compare the combination of Pembrolizumab and Lenvatinib to existing results with primary chemoradiatoin and brachytherapy to see if the combination of Pembrolizumab and Lenvatinib works to treat locally advanced cervical cancer.

Participants will:

  • Visit the clinic to receive Pembrolizumab intra venously once every 3 weeks for 5 cycles and then once very 6 weeks for a maximum of 2-years
  • Take Lenvatinib orally every day starting at the earliest 8 weeks after the last brachytherapy to a maximum of 1 year
  • Visit the clinic for checkups and tests during scheduled visits
Read the detailed description

Rationale Chemoradiation (CRT: combined external beam radiotherapy with weekly cisplatin) followed by brachytherapy has remained the standard first line treatment for locally advanced cervical (LACC) patients. Over the last decades, major improvements in radiotherapy have been pioneered through the EMBRACE studies. Most recently the outcome data of 1318 patients undergoing response adapted advanced MRI image guided intracavitary +/-interstitial brachytherapy (MR-IGABT) over and above CRT have been reported. This dose escalated approach resulted in 5-year local control of 92%, pelvic control of 87% and disease-free survival (DFS) of 68%. In this cohort, a 5-year OS of 64% was observed for stage IIIB and 67% for node positive patients. These results essentially confirm both the effectiveness of MR-IGABT for pelvic control but also the need of more effective systemic therapy approaches. Patients most at risk for recurrence and reduced 3-year DFS include patients with presence of multiple nodes in pelvic and paraaortic region or adeno/adenosquamous carcinoma histological type and those with a poor response to CRT.

Considering that both anti-angiogenesis and immune checkpoint blockade work independently in cervix cancer, a combination approach may be associated with synergy and improved outcomes. Recently, the phase III randomized placebo-controlled KEYNOTE A-18 trial investigated the combination of CRT with anti-PD-1 Pembrolizumab in patients with high-risk locally advanced cervical cancer defined as FIGO 2014 stage IB2-IIB with node-positive disease or stage III-IVA regardless of nodal status. With a median follow-up of 17·9 months a 11% progression free survival (PFS) benefit at 2-years was demonstrated (68% vs 57%). Timing immunotherapy during radiotherapy and close to brachytherapy (where high dose per fraction is utilised) may allow to maximally synchronize "immunotherapy response" by taking advantage of the "inflamed" tumour microenvironment and a high radiotherapy dose fraction that is administered using brachytherapy. Lenvatinib will be initiated not earlier than 8 weeks after the last CRT and brachytherapy, to allow for sufficient healing of acute side effects of CRT.

The study hypothesizes that over and above concurrent and Pembrolizumab monotherapy, the addition of Lenvatinib administered after CRT and brachytherapy will lead to improved outcomes in this high-risk population of patients with locally advanced cervical cancer.

Objective The primary objective of the trial is to evaluate progression free survival (PFS) at 24 months (by investigator assessed RECIST 1.1) in women with high-risk locally advanced cervical cancer treated with chemoradiotherapy and Pembrolizumab followed by Pembrolizumab and Lenvatinib. Secondary Objectives include overall survival (OS), local and regional control; physician reported toxicity (CTCAE v5.0) and patient reported outcomes (EORTC QLQ-C30 and CX-24); and associated tissue, blood and imaging based translational research.

Interventions Patients will undergo standard of care chemoradiation (CRT: combined external beam radiotherapy with weekly cisplatin). Initial tumor imaging at pre-screening must have been performed within 28 days prior to the date of registration. The site study team must review pre-treatment images to confirm the participant has measurable disease per RECIST 1.1 at diagnosis. Target definition and dose reporting follow ICRU-89 and are detailed in the protocol. The elective node target volume is risk based and follows EMBRACE-II, that includes elective para-aortic radiotherapy up to the crossing of the renal vessels in patients with: ≥ 1 pathologic node at common iliac or above OR ≥ 3 pathologic nodes. With regard to organs at risk (OAR) for bowel the outer loops are contoured including the mesenteric, and for bones the whole bone from ischial tuberosity to 25mm superior of the PTV is contoured.

Use of image guided intensity modulated radiotherapy (IG-IMRT) preferably with rotational IMRT is mandatory. 3D image guidance (Cone Beam CT (CBCT) or equivalent image guidance) before each EBRT fraction is mandatory. This allows for use of reduced PTV margins (5mm from ITV45). The dose to the PTV45 should be homogenous, with at least 95% of the PTV covered by the 95% prescription isodose, and dose maximum less than 107% of the prescribed dose. Special attention is needed for the OAR irradiation in close proximity to the CTV-T HR (bladder, rectum, sigmoid and bowel). A help contour with a margin of 10 mm is generated around the CTV-T HR (CTV-T HR +10mm). The dose within this help contour should be less than 103% of 45Gy to avoid hotspots in OAR walls which are likely to also receive considerable BT dose. Lymph nodes will be boosted by simultaneous integrated boost (SIB) technique. Use of coverage probability (CoP) dose planning principles for lymph node boosting is mandatory.

Although institutional practise for nodal boosting and dose levels can be followed, the recommendation given within this protocol for the nodal boost is that total EBRT + BT dose should preferably be in the range 55-60 Gy EQD2.Total dose to PTV-Ns of about 60 Gy EQD2 can be achieved with the following fractionation schedules:

  • Inside true pelvis: EBRT with SIB 25x2.2Gy= 55Gy physical dose. This schedule is equivalent to 56 Gy EQD2 EBRT + 3-4 Gy EQD2 from BT which results in a total dose of \~60 Gy EQD2.
  • Outside true pelvis: EBRT with SIB 25x2.3Gy =57.5 Gy physical dose. This schedule is equivalent to \~59 Gy EQD2 and BT dose contribution is negligible.

All patients should receive concurrent weekly cisplatin (40 mg/m2) during the 5 weeks of EBRT, based on standard institutional protocol. If possible, it may be advantageous to initiate EBRT and concomitant chemotherapy in the beginning of a week to avoid loss of 2 days in overall treatment time (OTT) already during the first weekend.

EBRT is followed by MRI guided adaptive brachytherapy (IGABT). The overall treatment time (OTT), defined from the first external beam fraction to the final external beam or brachytherapy fraction dose is delivered should be \< 50 days. To obtain maximal regression the treatment should always be initiated with EBRT and concomitant chemotherapy for 4-5 weeks before BT is applied in weeks. Systematic use of combined intracavitary and interstitial applicators (based on individual mould, ring, ovoids) is a preferred approach for appropriate dose adaptation which is dose escalation in particular for advanced parametrial disease and/or dose sparing in adjacent organs at risk. The first BT fraction has to be planned based on MRI with applicator in situ. Contouring for both tumour and OAR is performed for each insertion/implant of BT applicators by contouring on T2 weighted (para)-transversal MRI sequences in a dedicated 3D brachytherapy dose-planning system according to the GEC ESTRO Recommendations and the ICRU-89 report. Soft and hard dose planning constraints are detailed in the protocol. Doses are expressed as total EBRT and BT dose (each converted to EQD2). Hard constraints should be achieved in at least 90-95% of patients (per parameter), whereas soft constraints should be achieved in at least 70-80% of patients (per parameter). The priorities and balance between different DVH parameters are based on the therapeutic priorities (chance of tumor control versus risk of morbidity) as well as the level of evidence of dose effect for a given endpoint. Dose recording and reporting follows the recommendations of ICRU-89 report.

Standard of care CRT will be combined with the following study drugs:

Pembrolizumab: 5 intravenous administrations of Pembrolizumab (200 mg) every 3 weeks with the first administration at the start of chemoradiotherapy, followed by subsequent doses of 400 mg IV Pembrolizumab at 6 weeks intervals, starting week 16 up to week 102 with a maximum of 15 cycles. Pembrolizumab may be withheld after 1st year (week 54) in case of no evidence of disease. Lenvatinib: the combination with Lenvatinib will start after recovery of CRT, along with the 6 weekly cycles of Pembrolizumab, e.g. around 8-9 weeks after brachytherapy (week 16), at a dose of 20 mg daily oral and will continue up to week 48. Patients will be provided with a dosing card for Lenvatinib to complete during the treatment period. All patients will be asked to fill the dosing card once daily at the time of administrating Lenvatinib. It will include following information: dosing date, dose, dosing time, dosing missed and reason of missed dosing. They will be asked to bring the dosing card, along with their used medication packs, during their subsequent visit and will be used to assess compliance.

Haematology parameters and organ function will be checked through blood tests prior to each administration of Pembrolizumab and urine analysis prior to every other administration.

Tumor imaging is preferred to be acquired by computed tomography (CT) for uniform response evaluation. For the abdomen and pelvis, contrast-enhanced magnetic resonance imaging (MRI) may also be used when CT with iodinated contrast is contraindicated, or when local practice mandates it. MRI is the preferred modality for imaging the primary tumor when indicated. Initial tumor imaging at pre-screening (MRI and CT) must have been performed within 28 days prior to the date of registration. The site study team must review pre-treatment images to confirm the participant has measurable disease per RECIST 1.1 at diagnosis. Tumor imaging performed as part of routine clinical management is acceptable for use as screening tumor imaging if they are of diagnostic quality and performed within 28 days prior to the date of registration. Follow-up tumor imaging should be performed as per standard clinical practice. MRI is performed at 3 months and at 12 months (SOC), CT thorax/abdomen is performed at 12, 24 and 36 months. Based on clinical indications MRI may be repeated at 6 months (SOC).

Ethical considerations Ethical considerations relating to the clinical trial including the expected benefit to the individual subject or group of patients represented by the trial subjects as well as the nature and extent of burden and risks Pembrolizumab and Lenvatinib are cancer drugs that have proven to be effective against other cancers, both alone and in combination, such as for uterine cancer. Pembrolizumab also works well in combination with chemotherapy for advanced or metastatic cervical cancer and has been shown to be beneficial during and after chemoradiation for locally advanced cervical cancer. The study hypothesizes that over and above concurrent and Pembrolizumab monotherapy, the addition of Lenvatinib administered after CRT and brachytherapy will lead to improved outcomes in this population of locally advanced cervical cancer patients that are deemed to be at high risk of recurrence based on established risk factors.

Pembrolizumab and Lenvatinib may cause side effects (detailed in the protocol). Patients may experience side effects that can sometimes be serious or life-threatening, and/or side effects that may occur after you stopping Pembrolizumab. The side effects can occur in several tissues and organs at the same time. The following side effects of Pembrolizumab are common (may affect more than 10-20 people in 100 people receiving Pembrolizumab): Itchy skin; loose or watery stools, diarrhea, cough. The following side effects with Lenvatinib are common (may affect more than 1 in 10 people): high blood pressure; bleeding; bladder irritation or discomfort (cystitis); weight loss; diarrhoea.

Apart from side effects of the study drugs, taking part in the study will cost patients extra time, requires more and potentially longer stays in the hospital, and involves some discomfort from the additional measurements that are part of the study.

03

Conditions studied

  • Cervical Cancer by FIGO Stage 2018
  • Squamous Cell Carcinoma FIGO 2018 Stage IIIA, IIIB, IIIC1-IIIC2
  • Adenocarcinoma or Adeno-squamous Carcinoma Stage IB3-IIIC2

Keywords

  • cervical cancer
  • locally advanced cervical cancer
  • Pembrolizumab
  • Lenvatinib
  • radiotherapy
  • brachytherapy
  • high risk locally advanced cervical cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >18 years
  • (ECOG) performance status of 0 or 1.
  • High risk defined by either of the criteria:

    1. Squamous cell carcinoma FIGO 2018 stage IIIA, IIIB, IIIC1-IIIC2 OR
    2. Adenocarcinoma or adeno-squamous carcinoma Stage IB3-IIIC2.
  • Have adequate haematological parameters and organ function as defined in the protocol Table 3.
  • Have adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP ≤150/90 mm Hg.
  • Have based on 1.1 on imaging at diagnosis.
  • The participant provides written for the trial.
  • Patients should have been planned for radical chemoradiation and MR guided adaptive brachytherapy with intended treatment completion within 50 days.
  • Patients should be deemed suitable for start of Pembrolizumab during chemoradiation and brachytherapy, and for start of Lenvatinib/Pembrolizumab 8 weeks after last brachytherapy as per local investigators assessment.
  • Criteria for known and C positive subjects:

Hepatitis B and C screening tests are not required unless:

  • Known history of HBV or infection
  • As mandated by local health authority

Hepatitis B positive subjects:

  • Participants who are HBsAg positive are eligible if they have received HBV antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to inclusion.
  • Participants should remain on anti-viral therapy throughout study intervention and follow local guidelines for HBV anti-viral therapy post completion of study intervention.
  • Participants with history of HCV infection are eligible if HCV viral load is undetectable at screening.
  • Participants must have completed curative anti-viral therapy at least 4 weeks prior to randomization.

Exclusion criteria

Exclusion Criteria:

  • Patients with locally advanced cervical cancer and signs of organ wall involvement on MRI or non-gastrointestinal fistula.
  • Major surgery within 3 weeks prior to first dose of study interventions. Brachytherapy is not considered a major surgery.
  • Urine protein ≥1 g/24 hours. Note: Participants with proteinuria ≥2+ (≥100 mg/dL) on urine dipstick testing (or urinalysis) will undergo 24-hour urine collection for quantitative assessment of proteinuria.
  • If a or cardiac ultrasound was performed (on clinical indication): having a LVEF below the institutional (or local laboratory) normal range.
  • Radiographic evidence of encasement or invasion of a major blood vessel, or of intratumoral cavitation NOTE: the degree of proximity to major blood vessels should be considered because of the potential risk of severe hemorrhage associated with tumor shrinkage/necrosis following Lenvatinib therapy.
  • Prolongation of interval to >480 ms. NOTE: If the QTcF is prolonged to >480 ms in the presence of a pacemaker, contact the Sponsor to determine eligibility.
  • cardiovascular disease within 12 months from first dose of study intervention, including Class III or IV congestive heart failure, unstable angina, myocardial infarction, cerebral vascular accident, or cardiac arrhythmia associated with hemodynamic instability.

Note: Medically controlled arrhythmia would be permitted.

  • Gastrointestinal malabsorption or any other condition that might affect the absorption of Lenvatinib.
  • Active hemoptysis (bright red blood of at least 0.5 teaspoon) within 3 weeks prior to the first dose of study drug.
  • who has a positive urine pregnancy test within 72 hours prior to adjuvant phase. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. Note eligible patients for this trial are not WOCBP due to treatment with CRT.
  • Diagnosis of immunodeficiency or is receiving chronic systemic therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of therapy within 7 days prior to the first dose of study drug.
  • Known additional that is progressing or has required active treatment within the past 3 years.

Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin or carcinoma in situ, excluding carcinoma in situ of the bladder, that have undergone potentially curative therapy are not excluded.

  • Severe (≥Grade 3) to Pembrolizumab or Lenvatinib and/or any of its .
  • Active disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment and is allowed.
  • History of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
  • Active infection requiring systemic therapy.
  • Known history of (HIV) infection. Note: No HIV testing is required unless mandated by local health authority.
  • Known concurrent active (defined as HBsAg positive and detectable HBV DNA) and/or virus (defined as anti-HCV Ab positive and detectable HCV RNA [qualitative]) infection. See inclusion criteria 10

Note: no testing for Hepatitis B and Hepatitis C screening tests are not required unless:

  • Known history of HBV and HCV infection
  • As mandated by local health authority.

    • Has a history or current evidence of any condition, therapy, or laboratory abnormality or other circumstance that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or such that it is not in the best interest of the participant to participate, in the opinion of the treating investigator.
    • Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
    • Has had an allogenic tissue/solid organ transplant.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
87 participants (estimated)

Study arms

  • Experimental
    Single arm: Pembrolizumab and Lenvatinib

    Single arm open label study of Pembrolizumab and Lenvatinib in patients with high risk locally advanced cervix cancer that will undergo chemoradiation and brachytherapy

    Drug: pembrolizumab and lenvatinib

Interventions

  • Drugpembrolizumab and lenvatinib

    Drug pages: PembrolizumabStudies of PembrolizumabPembrolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · LenvatinibStudies of LenvatinibLenvatinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients will undergo standard of care chemoradiation (CRT: combined external beam radiotherapy with weekly cisplatin) followed by MRI guided brachytherapy, this will be combined with the following study drugs: Pembrolizumab: 5 intravenous administrations of Pembrolizumab (200 mg) every 3 weeks with the first administration at the start of chemoradiotherapy, followed by subsequent doses of 400 mg IV Pembrolizumab at 6 weeks intervals, starting week 16 up to week 102 with a maximum of 15 cycles. Lenvatinib: the combination with Lenvatinib will start after recovery, along with the 6 weekly cycles of Pembrolizumab, e.g. around 8-9 weeks after brachytherapy (week 16), at a dose of 20 mg daily oral and will continue up to week 48.

06

What researchers measure

Primary outcomes

  1. Progression Free Survival

    Actuarial Progression free survival (PFS) rate at 24 months, with a PFS event defined by either progression, using investigator assessed RECIST 1.1, or by death from any cause.

    Time frame: From date of enrollment to 24 months

Secondary outcomes

  1. Overall Survival

    Actuarial Overall Survival (OS) rate at 24 and at 36 months, with an OS event defined as death by any cause.

    Time frame: From date of enrollment to 24 and to 36 months

  2. Progression Free Survival

    Actuarial Progression free survival (PFS) rate at 36 months, with a PFS event defined by either progression, using investigator assessed RECIST 1.1, or by death from any cause.

    Time frame: From date of enrollment to 36 months

  3. Local Control

    Actuarial rate of Local Control (LC) of the primary tumor at 24 and 36 months, with an event defined as absence of tumor at the level of the cervix, detected at gynecological examination or imaging, and histological confirmed.

    Time frame: From date of enrollment to 24 and to 36 months.

  4. Regional Nodal Control

    Actuarial rate of Regional Nodal Control at 24 and 36 months, with an event defined as absence of pathological pelvic and / or para-aortic lymph node involvement assessed by imaging.

    Time frame: From date of enrollment to 24 and to 36 months.

  5. Adverse Events

    Adverse Events defined and graded by CTCAE v 5.0, crude and actuarial rates at 24 and 36 months.

    Time frame: From date of enrollment to 24 and 36 months.

  6. Patient reported symptoms and health related quality of life

    Patient reported symptoms and health related quality of life are determined using the validated EORTC QLQC30 and Cx-24 questionnaires.

    Time frame: At baseline prior to the start of treatment, at 5 weeks after start of treatment, at the first 6 weekly cycle of pembrolizumab, at 3, 6, 9, 12, 24, 36, 48 and 60 months.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Oct 2029, 43 months later.

Of 71 non-industry phase 2 interventional studies under Adenocarcinoma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 48 and three quarters within 94. This study's planned 43 months is below that.

Counting every sponsor, half of 93 studies reached it within 60 months; a quarter within 35 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2026
First posted
Jan 27, 2026
StartEst.
Mar 2026
Primary completionEst.
Oct 2029
CompletionEst.
Oct 2029
Last update
Jan 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07368985
Lead sponsor
Prof. Dr. Remi A. Nout
Responsible party
Prof. Dr. Remi A. Nout (Professor, Erasmus Medical Center) — Sponsor-investigator
First posted
Jan 27, 2026
Start date
Mar 2026 (estimated)
Primary completion
Oct 2029 (estimated)
Completion
Oct 2029 (estimated)
Last update
Jan 27, 2026

Study contacts

Remi A Nout, MD PhD
Contact
r.nout@erasmusmc.nl
+31 107041366
Ingrid Boere, MD
Contact
i.boere@erasmusmc.nl
+31 107034897

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pembrolizumab · Lenvatinib

Start the discussion